cancer

miR-375 a potential prognostic marker of head and neck cancers

January 25, 2012

Low-Level Expression of miR-375 Correlates with Poor Outcome and Metastasis While Altering the Invasive Properties of Head and Neck Squamous Cell Carcinomas. Researchers at Department of Pathology, Albert Einstein College of Medicine used global miRNA expression profiling of head and neck squamous cell carcinoma (HNSCC) samples and adjacent normal tissue to rank those miRNAs that [...]

Read the full article →

Rosetta Genomics Announces New York State Approval for miRview mets²

December 9, 2011

Proprietary microRNA Diagnostic for Identification of Cancer of Unknown Primary Now Available in All 50 U.S. States PHILADELPHIA, PA and REHOVOT, ISRAEL–(Marketwire – Dec 9, 2011) – Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announced that the New York State Department of Health has approved miRview® mets² for [...]

Read the full article →

Plasma Components Affect Accuracy of Circulating Cancer-Related MicroRNA Quantitation

December 7, 2011

New protocols improve detection of microRNAs for diagnosis Philadelphia, PA, — MicroRNAs (miRNAs) that regulate processes including fertilization, development, and aging show promise as biomarkers of disease. They can be collected from routinely collected fluids such as blood, saliva, and urine. However, a number of factors can interfere with the accuracy of miRNA tests. In [...]

Read the full article →

Study Shows Potential for microRNAs to Predict Gastric Cancer Recurrence

November 4, 2011

AIM: To compare the microRNA (miR) profiles in the primary tumor of patients with recurrent and non-recurrent gastric cancer. CONCLUSION: This study identified three miRs, miR-451, miR-199a-3p and miR-195 to be predictive of recurrence of gastric cancer. Of these, miR-451 had the strongest prognostic impact. PHILADELPHIA and REHOVOT, Israel, Nov. 4, 2011 /PRNewswire/ — Rosetta [...]

Read the full article →

MicroRNA Gene linked to Aggressive Skin Cancer

October 13, 2011

Epigenetic Regulation of MicroRNA Genes and the Role of miR-34b in Cell Invasion and Motility in Human Melanoma CLAREMONT, Calif., Oct. 13, 2011 /PRNewswire/ — A certain microRNA gene, miR-34b, could be a useful biomarker in early diagnosis of the most lethal forms of melanoma, according to new research published by KGI (Keck Graduate Institute) [...]

Read the full article →

Unexpected Link Between Cancer and Diabetes Revealed

September 29, 2011

New study connects the cancer gene Lin28 to glucose metabolism; may shed light on unifying principles in type 2 diabetes BOSTON, Sept. 29, 2011 /PRNewswire-USNewswire/ — A pathway activated in cancer plays an unexpected key role in metabolic diseases like type 2 diabetes, according to a study by researchers at Children’s Hospital Boston. Evidence that [...]

Read the full article →

Diabetes and cancer: A shared biological basis

September 29, 2011

Contrary to what you might think, cancer and diabetes appear to have some biology in common. According to a report in the September 30th issue of the Cell Press journal, Cell, a pathway that initially drew attention for its role in embryonic stem cells and cancer also influences the odds that mice develop or resist [...]

Read the full article →

MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines

September 23, 2011

Ovarian cancer is the leading cause of death from gynecologic cancer in women worldwide. According to the National Cancer Institute, ovarian cancer has the highest mortality rate among all the reproductive cancers in women. Advanced stage diagnosis and chemo/radio-resistance is a major obstacle in treating advanced ovarian cancer. The most commonly employed chemotherapeutic drug for [...]

Read the full article →

Small molecules shed light on cancer therapies

August 22, 2011

Patients suffering from an aggressive brain cancer will benefit from the results of a University of Illinois study that could advance the development of targeted gene therapies and improve prognosis. “We have advanced the understanding of the role of microRNAs on glioblastoma multiforme, a deadly brain cancer, by studying the networks between the microRNAs and [...]

Read the full article →

Rosetta Genomics and UC Davis Researchers to Develop and Validate microRNA Biomarker to Predict Response to Neoadjuvant Chemotherapy in Bladder Cancer

June 28, 2011

PHILADELPHIA and REHOVOT, Israel, June 28, 2011 /PRNewswire/ – Rosetta Genomics (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announces it has entered into a collaboration with the University of California,  Davis (“UC Davis” or the “University”) to develop and validate a microRNA profile for muscle-invasive bladder cancer (MI-BC) that is [...]

Read the full article →

← Previous Entries

Next Entries →